Crossmark

Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-67528-4

Published Online: 2025-12-18

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tang, Jing https://orcid.org/0000-0003-1013-147X
Yang, Yongqiang https://orcid.org/0009-0007-0043-6073
Liu, Dongen https://orcid.org/0009-0000-9019-765X
Wang, Bicheng https://orcid.org/0000-0002-4598-7721
Lin, Zhenyu

Wu, Zilong

Zhang, Jinfeng

Zhang, Dejun

Liu, Yaqin

Ge, Minghui

Chen, Lei https://orcid.org/0000-0002-9380-9559
Wu, Gang https://orcid.org/0000-0001-6558-3508
Zhang, Tao https://orcid.org/0000-0003-4018-3393
Xue, Jun https://orcid.org/0000-0001-7323-0331
License Information

Text and Data Mining valid from 2025-12-18

Version of Record valid from 2026-01-21
More Information

Article History

Received: 9 February 2025

Accepted: 2 December 2025

First Online: 18 December 2025

Competing interests

: L.Y.Q. and G.M.H. declare employment with Nanjing Simcere Medical Laboratory Science Co., Ltd. The remaining authors declare that they have no competing interests.

Document is current

Any future updates will be listed below